Diseases /

Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11

Back to Diseases List
Associated Genetic Biomarkers

Overview

NCI Definition: An acute myeloid leukemia with monocytic and granulocytic differentiation and the presence of a characteristically abnormal eosinophil component in the bone marrow. This type of acute myeloid leukemia has a favorable prognosis. (WHO, 2001) [1]

Acute myeloid leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11s most frequently harbor alterations in FLT3, NRAS, KIT, WT1, and KRAS [2].

Most Commonly Altered Genes in Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11

FLT3 Mutation, NRAS Mutation, KIT Mutation, KIT Exon 17 Mutation, and KIT Codon 816 Missense are the most common alterations in acute myeloid leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 [2].

Top Alterations in Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11

Clinical Trials

View Clinical Trials for Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11

Significant Genes in Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11

CBFB +

MYH11 +

RUNX1 +

RUNX1T1 +

Disease Details

Synonyms
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11, Acute Myeloid Leukemia, CBF-beta/MYH11, Acute Myeloid Leukemia, CBFB-MYH11, Acute Myeloid Leukemia with Abnormal Marrow Eosinophils
Parent(s)
Core Binding Factor Acute Myeloid Leukemia
OncoTree Name
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11
OncoTree Code
AMLCBFBMYH11

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.